Kymera Therapeutics (KYMR) has announced significant progress across its clinical programs, including updates on its IRAK4 and STAT6 programs in partnership with Sanofi, and its oncology programs KT-253 and KT-333. The company's Q2 2024 earnings call highlighted advancements in targeted protein degradation therapies and a strong financial position to support ongoing research and development.
Immunology Pipeline Advancements
Kymera's IRAK4 program, featuring KT-474, has shown TYK degradation of IRAK4 in blood and skin, impacting biomarkers of inflammation in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients. Sanofi intends to expand the Phase II trials in HS and AD, aiming to accelerate the path to Phase III studies. This decision follows an interim review of safety and efficacy data by an independent data monitoring committee.
The STAT6 program is advancing with KT-621, an oral degrader targeting STAT6, a selective transcription factor of the IL-4/13 pathway. Preclinical studies have demonstrated that KT-621 is more potent than dupilumab at blocking TH2 signaling in cell systems and equally or superior at blocking TH2 inflammation in preclinical disease models. A Phase I trial is expected to commence soon, with data anticipated in the first half of 2025. All IND-enabling studies have been completed with no safety findings of any kind.
Oncology Program Updates
The oncology programs KT-253 and KT-333 have shown promising activity and tolerability in Phase I trials. KT-253, targeting MDM2, has demonstrated the ability to overcome the MDM2 feedback loop and rapidly induce apoptosis. Data from the Phase I dose escalation trial showed potent upregulation of p53 pathway biomarkers and signs of antitumor activity in multiple tumor types. Enrollment for the Phase III trial of KT-253 is expected to be completed in the second half of 2024.
KT-333, a potent and highly selective degrader of STAT3, has shown strong target knockdown in blood and tumor, induction of interferon gamma response, and preliminary clinical efficacy in lymphomas at tolerated doses. Complete responses were observed in heavily pretreated Hodgkin's lymphoma patients who had progressed after prior checkpoint inhibitor therapy and anti-CD30 ADC. Enrollment of additional Hodgkin's lymphoma patients is ongoing, with data expected in the second half of 2024.
Financial Overview
Kymera reported Q2 2024 revenue of $25.7 million, primarily from its partnership with Sanofi. Research and development expenses were $59.2 million, and general and administrative expenses were $17.4 million. The company's cash balance stands at $702 million, expected to fund operations into the first half of 2027.
Future Outlook
Kymera is optimistic about the clinical benefits of its IRAK4 and STAT6 programs and expects to share Phase I data for its immunology programs in 2025. The company is also exploring indication expansion for the KT-474 program in respiratory, GI inflammation, and rheumatology diseases. Kymera is working on a TYK2 program targeting IL-23, IL-12, and Type 1 interferon pathways, with Phase I studies underway.
